CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, ...
Integrative CSF proteomics and lipidomics revealed protein–lipid network disruptions in Alzheimer’s disease. Mixed molecular ...
Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease ...
Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...
Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most ...
How does the brain clean itself during sleep? A new ultrafast MRI method tracks cerebrospinal fluid flow without contrast ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company”), a clinical-stage pharmaceutical company developing targeted ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...
Italian climber Domenico Pozzovivo has announced he is returning from retirement and has signed with Solution Tech-Nippo-Rali ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results